SCHEMBL4868822

SCHEMBL4868822

Oc1cc(C(F)(F)F)cc(Br)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
HIF1A Q16665 3/20 0.46
ALOX15 P16050 2/20 0.46
ALOX12 P18054 2/20 0.46
CYP3A4 P08684 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
CASP1 P29466 1/20 0.46
RECQL P46063 1/20 0.46
CHEK1 O14757 1/20 0.39
DAPK3 O43293 1/20 0.39
RET P07949 1/20 0.39
PDGFRB P09619 1/20 0.39
PIM1 P11309 1/20 0.39
PDGFRA P16234 1/20 0.39
KDR P35968 1/20 0.39
MAPK8 P45983 1/20 0.39
RPS6KA3 P51812 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10699329 0.88 TSHR (0.58) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL15729337 0.84 TSHR (0.45) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL30572925 0.80 ALOX15 (0.35) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL20974042 0.80 TSHR (0.50) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL29068704 0.80 ALOX15 (0.35) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL23899710 0.78 CHEK1 (0.37) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL17026779 0.78 ALDH1A1 (0.43) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL22119936 0.78 HPGD (0.37) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL18894012 0.78 ALDH1A1 (0.43) TSHRHIF1AALOX15ALOX12CYP3A4
SCHEMBL16345264 0.78 CHEK1 (0.66) TSHRHIF1AALOX15ALOX12CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 TSHR 1228/4885HIF1A 1034/4885ALOX15 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.